Across TCGA pan-cancer cohorts, ATXN3L mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ATXN3L data layer compared with 8 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATXN3L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATXN3L expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
PDAC are the cancer types where ATXN3L mass-spec protein most reproducibly stratifies survival.